Hi everyone! The Schug Lab is searching for a Lab Manager. If you are interested, please have a look through the job description and apply through the link below. This position is funded through new grant support. jeffersonhealth.wd5.myworkda…

NEW: Today, I’m releasing a Surgeon General’s Advisory on the causal link between alcohol consumption and increased cancer risk. Alcohol is the 3rd leading preventable cause of cancer in the U.S., contributing to about 100,000 cancer cases and 20,000 cancer deaths each year.

Happy to announce our collaboration with @Tcellogic on metabolic features of exhausted T cells is now out in @ScienceMagazine. TL;DR they can't use acetate to fuel their function. Great work by Shixin Ma and Mike Dahabieh. science.org/doi/10.1126/scie…

Our work on metabolism of quiescent cells! A bit of a new area for us in collaboration with the Buckanovich lab

Thanks to support from @TheVFoundation, @NanZhangWistar and @AuslanderNoam have been named as V Scholars and awarded $1.2 million in grant funding to support research that aims to improve existing cancer therapies. Our story: bit.ly/4gudEpE

Excited to share our latest study on ACSS1 and acetate metabolism in cancer, which was spearheaded by two graduate students in the lab. Stay tuned for more exciting news from the Schug Lab!

My baby girl came on Monday night and closing the week with a first author paper from @DrRGJonesLab ! What a week!! Many thanks to everyone for all the efforts to get this paper out!!

No amount of alcohol is safe but the risk of limited consumption is limited but dictated by underlying conditions. This is an excellent summary of meta-analyses ⁦@nytimes⁩ nytimes.com/2024/06/15/magaz…

New preprint from the lab is online! The product of a stellar collaboration with @Muir_Lab, we explore a chemically defined physiologic media formulation based of the metabolite of tumor interstitial fluid (TIF, or “tumor juice”) and its effects on T cell function! A brief 🧵1/

Meet Nathaniel W. Snyder @mzspectrum Winner of the 2024 Chemical Research in Toxicology Young Investigator Award! Read our interview here 🔗 go.acs.org/9HM

Happy to report that our paper, where we grapple with the mystery of ACLY splice isoforms, is finally out! jbc.org/article/S0021-9258(2… @WellenLab @MarmorsteinLab

🔬 Excited to share @SchugLab’s latest findings at #ASMS2024! Join me at the poster session where we’ll delve into: 1. Targeted Metabolomics. 2. FASN (Fatty Acid Synthase) and fatty acid biosynthesis. 3. Coenzymes A, malonate, and succinate. 4. Mitochondria (should I add ‘powerhouses’?). ➡️ ThP133, Thu, June 6, 10:30 am ⬅️ See you there! 🌟🧪📊 #TeamMassSpec

Happy to share our new paper in print today in @ScienceAdvances exploring nutrient utilization by CD8 T effector cells in vivo using infusion of 13C tracers. Great work by Eric Ma, Mike Dahabieh and collaborators at @VAInstitute and @AgiosPharma. science.org/doi/10.1126/scia…

Happy to @SchugLab’s latest findings! We set out to establish the metabolic signature created by FASN inhibition and discovered, along the way, that three widely used FASN inhibitors likely do not inhibit FASN in cells. See project leader @dzmitrybio for a thread!

I am excited to share our preprint "Identification of Fasnall as a therapeutically effective Complex I inhibitor." biorxiv.org/content/10.1101/… Several things from inside 👇 We asked a question: What happens with the polar metabolome of cancer cells when fatty acid synthase (FASN) is inhibited? We found that three widely used FASN inhibitors likely do not inhibit FASN in cells. Instead, we reassign one of them, Fasnall, as a new Complex I inhibitor. Fasnall can reach therapeutic concentrations in vivo and effectively prevent tumor growth in several OXPHOS-dependent tumor models (breast cancer xenografts and one model of BRAFi/MEKi double-resistant melanoma PDX). Fasnall joins the set of known Complex I inhibitors, such as rotenone, metformin, mubritinib, and IACS-010759. Unlike the latter, Fasnall seemingly does not cause painful neuropathies in vivo. Mubritinib (TAK-165) was previously known as an ERBB2 inhibitor, and its activity was reassessed in the work by Baccelli et al. (2019). 🧵

We are proud of the work one of our grantees, @SchugLab, is doing @TheWistar for breast cancer research. They've proven that the immune system can help kick Triple Negative Breast Cancer out! While still early, Our CSO, Dr. @susannagreer, puts it into perspective!

ONLINE NOW @NatureCancer “Acetate acts as a metabolic immunomodulator by bolstering T-cell effector function and potentiating antitumor immunity in breast cancer” by #ZacharySchug & Co. nature.com/articles/s43018-0… rdcu.be/dndEL

1/ Excited to see this article published @NatureCancer. In a brilliant collaboration with Jürgen Ruland, Tim Wartewig, @Jay___Daniels, and Miriam Schulz discovered the mechanisms by which PD1 constrains T cell lymphomagenesis. nature.com/articles/s43018-0…